0001708138-20-000043.txt : 20200420
0001708138-20-000043.hdr.sgml : 20200420
20200420192735
ACCESSION NUMBER: 0001708138-20-000043
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20200416
FILED AS OF DATE: 20200420
DATE AS OF CHANGE: 20200420
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: LAROSA JOSEPH J
CENTRAL INDEX KEY: 0001238303
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 000-19034
FILM NUMBER: 20803682
MAIL ADDRESS:
STREET 1: 777 OLD SAW MILL RIVER ROAD
CITY: TARRYTOWN
STATE: NY
ZIP: 10591
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: REGENERON PHARMACEUTICALS, INC.
CENTRAL INDEX KEY: 0000872589
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 133444607
STATE OF INCORPORATION: NY
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 777 OLD SAW MILL RIVER ROAD
CITY: TARRYTOWN
STATE: NY
ZIP: 10591
BUSINESS PHONE: 9148477000
MAIL ADDRESS:
STREET 1: 777 OLD SAW MILL RIVER ROAD
CITY: TARRYTOWN
STATE: NY
ZIP: 10591
FORMER COMPANY:
FORMER CONFORMED NAME: REGENERON PHARMACEUTICALS INC
DATE OF NAME CHANGE: 19930328
4
1
edgardoc.xml
PRIMARY DOCUMENT
X0306
4
2020-04-16
0
0000872589
REGENERON PHARMACEUTICALS, INC.
REGN
0001238303
LAROSA JOSEPH J
777 OLD SAW MILL RIVER ROAD
TARRYTOWN
NY
10591
0
1
0
0
EVP General Counsel and Secret
Common Stock
2020-04-20
4
S
0
669
567.3
D
15547
D
Common Stock
2020-04-20
4
S
0
234
569.41
D
15313
D
Common Stock
2020-04-20
4
S
0
125
570.27
D
15188
D
Common Stock
2020-04-20
4
S
0
112
571.65
D
15076
D
Common Stock
2020-04-20
4
S
0
61
572.94
D
15015
D
Common Stock
2020-04-20
4
S
0
577
573.59
D
14438
D
Common Stock
287
I
By 401(k) Plan
Non-Qualified Stock Option (right to buy)
59.2
2020-04-16
4
M
0
5000
0.0
D
2021-09-01
Common Stock
5000
29933
D
Non-Qualified Stock Option (right to buy)
59.2
2020-04-17
4
M
0
6622
0.0
D
2021-09-01
Common Stock
6622
23311
D
Non-Qualified Stock Option (right to buy)
59.2
2020-04-17
4
M
0
5000
0.0
D
2021-09-01
Common Stock
5000
18311
D
Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c).
Represents volume-weighted average price of sales of 669 shares of Company stock on April 20, 2020 at prices ranging from $567.00 to $567.76. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on April 20, 2020 at each separate price.
Represents volume-weighted average price of sales of 234 shares of Company stock on April 20, 2020 at prices ranging from $569.22 to $569.82. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on April 20, 2020 at each separate price.
Represents volume-weighted average price of sales of 125 shares of Company stock on April 20, 2020 at prices ranging from $570.03 to $570.50. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on April 20, 2020 at each separate price.
Represents volume-weighted average price of sales of 577 shares of Company stock on April 20, 2020 at prices ranging from $573.31 to $573.82. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on April 20, 2020 at each separate price.
The stock option award (combined incentive stock option and non-qualified stock option) vests in four equal annual installments, commencing one year after the date of grant.
Form two of two
/s/**Joseph J. LaRosa
2020-04-20